Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Stuart J. Wong MD

Stuart J. Wong MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center


Publications (36)

  • Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. (Sun A, Hu C, Wong SJ, Gore E, Videtic G, Dutta S, Suntharalingam M, Chen Y, Gaspar LE, Choy H) JAMA Oncol 2019 Jun 01;5(6):847-855 PMID: 30869743 PMCID: PMC6459052 SCOPUS ID: 2-s2.0-85062993057 03/15/2019       3 Citations
  • Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-institutional Study. (Zenga J, Graboyes E, Janz T, Drake V, Rettig E, Desai S, Nickel C, Shabani S, Padhya T, Scarpinato M, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P) Otolaryngol Head Neck Surg 2019 Jul;161(1):74-81 PMID: 30753110 SCOPUS ID: 2-s2.0-85061834834 02/13/2019    
  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. (Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R) Eur J Cancer 2019 Jan;107:142-152 PMID: 30576970 SCOPUS ID: 2-s2.0-85058541688 12/24/2018       13 Citations
  • E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. (Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM) Clin Cancer Res 2019 Jan 15;25(2):524-532 PMID: 30420448 PMCID: PMC6335150 SCOPUS ID: 2-s2.0-85060063447 11/14/2018       1 Citation
  • In Regard to Bossi et al. (Fakhry C, Nguyen-Tân PF, Lambert L, Rosenthal DI, Weber RS, Gillison ML, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT) Int J Radiat Oncol Biol Phys 2018 11 01;102(3):669-670 PMID: 30238902 SCOPUS ID: 2-s2.0-85053320936 09/22/2018       1 Citation
  • Reirradiation for Head and Neck Cancer: The Who and the How. (Margalit DN, Wong SJ) Int J Radiat Oncol Biol Phys 2018 03 01;100(3):618-620 PMID: 29413275 SCOPUS ID: 2-s2.0-85044236227 02/08/2018       3 Citations
  • Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. (Awan MJ, Nedzi L, Wang D, Tumati V, Sumer B, Xie XJ, Smith I, Truelson J, Hughes R, Myers LL, Lavertu P, Wong S, Yao M) Ann Oncol 2018 04 01;29(4):998-1003 PMID: 29346519 SCOPUS ID: 2-s2.0-85046676913 01/19/2018       2 Citations
  • Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. (Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S) Case Rep Oncol 2017 Sep-Dec;10(3):897-909 PMID: 29279690 PMCID: PMC5731100 12/28/2017    
  • Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. (Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML) J Clin Oncol 2017 Dec 20;35(36):4057-4065 PMID: 28777690 PMCID: PMC5736236 SCOPUS ID: 2-s2.0-85033804691 08/05/2017       27 Citations
  • The Not Knowing Is the Hardest Part. (Shukla ME, Wong SJ) Int J Radiat Oncol Biol Phys 2017 04 01;97(5):1051-1053 PMID: 28332988 03/24/2017    
  • Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. (Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW) Clin Cancer Res 2016 Dec 15;22(24):6061-6068 PMID: 27334835 SCOPUS ID: 2-s2.0-85007020561 06/24/2016       41 Citations
  • Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out? (Saba NF, Wong SJ) J Clin Oncol 2016 06 10;34(17):2072-3 PMID: 27069073 SCOPUS ID: 2-s2.0-84971673823 04/14/2016       2 Citations
  • Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. (Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE) Ann Oncol 2016 Feb;27(2):318-23 PMID: 26598548 PMCID: PMC4722891 SCOPUS ID: 2-s2.0-84961620192 11/26/2015       21 Citations
  • Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. (Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE) Cancer Immunol Res 2015 May;3(5):567-74 PMID: 25769300 PMCID: PMC4681575 SCOPUS ID: 2-s2.0-84962277989 03/15/2015       17 Citations
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. (Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2015 Jan 01;91(1):116-23 PMID: 25446610 PMCID: PMC4385459 SCOPUS ID: 2-s2.0-84922975792 12/03/2014       15 Citations
  • EGFRvIII expression in squamous cell carcinoma of the skin. (Dziunycz PJ, Lazarova Z, Duncan N, Wong S, Neuburg M, Hofbauer GF, Olasz EB) JAMA Dermatol 2013 Oct;149(10):1240-2 PMID: 23986462 SCOPUS ID: 2-s2.0-84885940634 08/30/2013       7 Citations
  • A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. (Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EEW, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E) Oral Oncol 2013 Sep;49(9):970-976 PMID: 23845699 PMCID: PMC4456032 SCOPUS ID: 2-s2.0-84883087653 07/13/2013       14 Citations
  • Neoadjuvant versus induction chemotherapy: more than semantics. (Devisetty K, Wong SJ) J Clin Oncol 2013 Aug 10;31(23):2971-2 PMID: 23733777 SCOPUS ID: 2-s2.0-84889851222 06/05/2013       1 Citation
  • Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. (Johnson A, Tarima S, Wong S, Friedland DR, Runge CL) JAMA Otolaryngol Head Neck Surg 2013 Mar;139(3):256-64 PMID: 23429908 SCOPUS ID: 2-s2.0-84875829521 02/23/2013       2 Citations
  • Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. (Randhawa J, Wong S, Atallah E, Olasz E) Int J Dermatol 2014 Jan;53(1):e13-4 PMID: 22998756 SCOPUS ID: 2-s2.0-84890794842 09/25/2012       2 Citations
  • Retreatment of recurrent head and neck cancer in a previously irradiated field. (Wong SJ, Bourhis J, Langer CJ) Semin Radiat Oncol 2012 Jul;22(3):214-9 PMID: 22687946 SCOPUS ID: 2-s2.0-84862137892 06/13/2012       11 Citations
  • Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). (Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy BA, Wong SJ, Bellm LA, Schwartz M, Newman J, Adkins D, Hayes DN, Parvathaneni U, Brachman D, Ghabach B, Schneider CJ, Greenberg M, Anné PR) Cancer 2012 Dec 01;118(23):5783-92 PMID: 22569917 SCOPUS ID: 2-s2.0-84869490978 05/10/2012       33 Citations
  • A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. (de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE) Clin Cancer Res 2012 Apr 15;18(8):2336-43 PMID: 22371453 PMCID: PMC4467891 SCOPUS ID: 2-s2.0-84859873106 03/01/2012       75 Citations
  • Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. (Kharofa J, Choong N, Wang D, Firat S, Schultz C, Sadasiwan C, Wong S) Int J Radiat Oncol Biol Phys 2012 Jun 01;83(2):690-5 PMID: 22112556 SCOPUS ID: 2-s2.0-84861097469 11/25/2011       19 Citations
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. (Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG) Int J Radiat Oncol Biol Phys 2012 Mar 15;82(4):1367-75 PMID: 21775070 PMCID: PMC3208721 SCOPUS ID: 2-s2.0-84857921757 07/22/2011       41 Citations
  • How does TPF improve survival over PF? (Devisetty K, Wong SJ, Mell LK) Lancet Oncol 2011 May;12(5):419-20; author reply 421-2 PMID: 21536218 SCOPUS ID: 2-s2.0-79955460481 05/04/2011       3 Citations
  • Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. (Wong SJ, Harari PM, Garden AS, Schwartz M, Bellm L, Chen A, Curran WJ, Murphy BA, Ang KK) Cancer 2011 Apr 15;117(8):1679-86 PMID: 21472715 SCOPUS ID: 2-s2.0-79953797936 04/08/2011       33 Citations
  • Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. (Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, Massey BL, Blumin J, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2011 Dec 01;81(5):e825-32 PMID: 21300450 SCOPUS ID: 2-s2.0-81855184909 02/09/2011       35 Citations
  • Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. (Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H) J Clin Oncol 2011 Jan 20;29(3):272-8 PMID: 21135270 PMCID: PMC3056462 SCOPUS ID: 2-s2.0-79951964973 12/08/2010       179 Citations
  • Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. (Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H) J Clin Oncol 2011 Jan 20;29(3):279-86 PMID: 21135267 PMCID: PMC3056463 SCOPUS ID: 2-s2.0-79951963826 12/08/2010       210 Citations
  • Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. (Murphy BA, Chen A, Curran WJ Jr, Garden AS, Harari PM, Wong SJ, Ang KK) Support Care Cancer 2009 Nov;17(11):1393-401 PMID: 19263090 SCOPUS ID: 2-s2.0-70350173397 03/06/2009       11 Citations
  • Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. (Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH, Massey BL, Wilson JF, Wang D) Int J Radiat Oncol Biol Phys 2008 Mar 01;70(3):678-84 PMID: 18262086 SCOPUS ID: 2-s2.0-38849083351 02/12/2008       75 Citations
  • Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? (Wong SJ, Machtay M, Li Y) J Clin Oncol 2006 Jun 10;24(17):2653-8 PMID: 16763279 SCOPUS ID: 2-s2.0-33748177338 06/10/2006       92 Citations
  • Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. (Wang D, Schultz CJ, Jursinic PA, Bialkowski M, Zhu XR, Brown WD, Rand SD, Michel MA, Campbell BH, Wong S, Li XA, Wilson JF) Int J Radiat Oncol Biol Phys 2006 May 01;65(1):143-51 PMID: 16618577 SCOPUS ID: 2-s2.0-33645964284 04/19/2006       113 Citations
  • Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. (Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR) Clin Cancer Res 2001 Nov;7(11):3574-9 PMID: 11705879 SCOPUS ID: 2-s2.0-0035181433 11/14/2001       75 Citations
  • Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. (Wong SJ, Myette MS, Wereley JP, Chitambar CR) Clin Cancer Res 1999 Feb;5(2):439-43 PMID: 10037195 SCOPUS ID: 2-s2.0-0032972705 02/26/1999       18 Citations
  • Last update: 04/19/2019
    jenkins-FCD Prod-387 b0ced2662056320369de4e5cd5f21c218c03feb3